TY - JOUR
T1 - Ebola virus convalescent blood products
T2 - Where we are now and where we may need to go
AU - Burnouf, Thierry
AU - Seghatchian, Jerard
PY - 2014
Y1 - 2014
N2 - The world is regularly exposed to emerging infections with the potential to burst into a pandemic. One possible way to treat patients, when no other treatment is yet developed, is passive immunization performed by transfusing blood, plasma or plasma immunoglobulin fractions obtained from convalescent donors who have recovered from the disease and have developed protective antibodies. The most recent on-going epidemic is caused by the Ebola virus, a filovirus responsible for Ebola virus disease, a severe, often lethal, hemorrhagic fever. Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease. This publication provides an overview of the various convalescent blood products and technological options that could theoretically be considered when there is a need to rely on this therapeutic approach. In countries without access to advanced blood-processing technologies, the choice may initially be restricted to convalescent whole blood or plasma. In technologically advanced countries, additional options for convalescent blood products are available, including virally inactivated plasma and fractionated immunoglobulins. The preparation of minipool immunoglobulins is also a realistic option to consider.
AB - The world is regularly exposed to emerging infections with the potential to burst into a pandemic. One possible way to treat patients, when no other treatment is yet developed, is passive immunization performed by transfusing blood, plasma or plasma immunoglobulin fractions obtained from convalescent donors who have recovered from the disease and have developed protective antibodies. The most recent on-going epidemic is caused by the Ebola virus, a filovirus responsible for Ebola virus disease, a severe, often lethal, hemorrhagic fever. Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease. This publication provides an overview of the various convalescent blood products and technological options that could theoretically be considered when there is a need to rely on this therapeutic approach. In countries without access to advanced blood-processing technologies, the choice may initially be restricted to convalescent whole blood or plasma. In technologically advanced countries, additional options for convalescent blood products are available, including virally inactivated plasma and fractionated immunoglobulins. The preparation of minipool immunoglobulins is also a realistic option to consider.
KW - Blood
KW - Convalescent plasma
KW - Ebola
KW - Emerging pathogens
KW - Immunoglobulins
KW - Mini-pool
KW - Plasma
KW - Transfusion
KW - Viral inactivation
KW - Virus
UR - http://www.scopus.com/inward/record.url?scp=84922620862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922620862&partnerID=8YFLogxK
U2 - 10.1016/j.transci.2014.10.003
DO - 10.1016/j.transci.2014.10.003
M3 - Review article
C2 - 25457751
AN - SCOPUS:84922620862
SN - 1473-0502
VL - 51
SP - 120
EP - 125
JO - Transfusion and Apheresis Science
JF - Transfusion and Apheresis Science
IS - 2
ER -